• Je něco špatně v tomto záznamu ?

Investigating the Molecular Basis for the Selective Inhibition of Aldehyde Dehydrogenase 2 by the Isoflavonoid Daidzin

TT. da Silva Cunha, FR. de Souza, P. de Sena Murteira Pinheiro, CMR. de Sant'Anna, F. Noël, TC. Costa França, CA. Manssour Fraga

. 2020 ; 19 (6) : 437-447. [pub] -

Jazyk angličtina Země Spojené arabské emiráty

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004892

Grantová podpora
E-02/202.961/2017, E- 26/202.878/2018 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro [FAPERJ]
465.249/2014-0 National Institute of Science and Technology in Drugs and Medicines (INCTINOFAR)

BACKGROUND: ALDH-2 has been considered an important molecular target for the treatment of drug addiction due to its involvement in the metabolism of the neurotransmitter dopamine: however, the molecular basis for the selective inhibition of ALDH-2 versus ALDH-1 should be better investigated to enable a more pragmatic approach to the design of novel ALDH-2 selective inhibitors. OBJECTIVE: In the present study, we investigated the molecular basis for the selective inhibition of ALDH-2 by the antioxidant isoflavonoid daidzin (IC50 = 0.15 μM) compared to isoform 1 of ALDH through molecular dynamics studies and semiempirical calculations of the enthalpy of interaction. METHODS: The applied methodology consisted of performing the molecular docking of daidzin in the structures of ALDH-1 and ALDH-2 and submitting the lower energy complexes obtained to semiempirical calculations and dynamic molecular simulations. RESULTS: Daidzin in complex with ALDH-2 presented directed and more specific interactions, resulting in stronger bonds in energetic terms and, therefore, in enthalpic gain. Moreover, the hydrophobic subunits of daidzin, in a conformationally more restricted environment (such as the catalytic site of ALDH-2), promote the better organization of the water molecules when immersed in the solvent, also resulting in an entropic gain. CONCLUSION: The molecular basis of selective inhibition of ALDH-2 by isoflavonoids and related compounds could be related to a more favorable equilibrium relationship between enthalpic and entropic features. The results described herein expand the available knowledge regarding the physiopathological and therapeutic mechanisms associated with drug addiction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004892
003      
CZ-PrNML
005      
20220127144844.0
007      
ta
008      
220113s2020 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1871527319999200817153150 $2 doi
035    __
$a (PubMed)32811404
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a da Silva Cunha, Thayssa Tavares $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
245    10
$a Investigating the Molecular Basis for the Selective Inhibition of Aldehyde Dehydrogenase 2 by the Isoflavonoid Daidzin / $c TT. da Silva Cunha, FR. de Souza, P. de Sena Murteira Pinheiro, CMR. de Sant'Anna, F. Noël, TC. Costa França, CA. Manssour Fraga
520    9_
$a BACKGROUND: ALDH-2 has been considered an important molecular target for the treatment of drug addiction due to its involvement in the metabolism of the neurotransmitter dopamine: however, the molecular basis for the selective inhibition of ALDH-2 versus ALDH-1 should be better investigated to enable a more pragmatic approach to the design of novel ALDH-2 selective inhibitors. OBJECTIVE: In the present study, we investigated the molecular basis for the selective inhibition of ALDH-2 by the antioxidant isoflavonoid daidzin (IC50 = 0.15 μM) compared to isoform 1 of ALDH through molecular dynamics studies and semiempirical calculations of the enthalpy of interaction. METHODS: The applied methodology consisted of performing the molecular docking of daidzin in the structures of ALDH-1 and ALDH-2 and submitting the lower energy complexes obtained to semiempirical calculations and dynamic molecular simulations. RESULTS: Daidzin in complex with ALDH-2 presented directed and more specific interactions, resulting in stronger bonds in energetic terms and, therefore, in enthalpic gain. Moreover, the hydrophobic subunits of daidzin, in a conformationally more restricted environment (such as the catalytic site of ALDH-2), promote the better organization of the water molecules when immersed in the solvent, also resulting in an entropic gain. CONCLUSION: The molecular basis of selective inhibition of ALDH-2 by isoflavonoids and related compounds could be related to a more favorable equilibrium relationship between enthalpic and entropic features. The results described herein expand the available knowledge regarding the physiopathological and therapeutic mechanisms associated with drug addiction.
650    _2
$a aldehyddehydrogenasa $x metabolismus $7 D000444
650    _2
$a dopamin $x metabolismus $7 D004298
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a isoflavony $x farmakologie $7 D007529
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a poruchy spojené s užíváním psychoaktivních látek $x farmakoterapie $7 D019966
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Souza, Felipe Rodrigues $u Laboratory of Molecular Modeling Applied to the Chemical and Biological Defense (LMACBD), Military Institute of Engineering, Rio de Janeiro, RJ, Brazi
700    1_
$a de Sena Murteira Pinheiro, Pedro $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
700    1_
$a de Sant'Anna, Carlos Maurício Rabello $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Department of Fundamental Chemistry, Chemistry Institute, Federal Rural University of Rio de Janeiro, Seropédica, RJ, Brazi
700    1_
$a Noël, François $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Laboratory of Molecular Biochemical and Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
700    1_
$a Costa França, Tanos Celmar $u Laboratory of Molecular Modeling Applied to the Chemical and Biological Defense (LMACBD), Military Institute of Engineering, Rio de Janeiro, RJ, Brazi $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republi
700    1_
$a Manssour Fraga, Carlos Alberto $u Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi $u Graduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazi
773    0_
$w MED00173402 $t CNS & neurological disorders drug targets $x 1996-3181 $g Roč. 19, č. 6 (2020), s. 437-447
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32811404 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144840 $b ABA008
999    __
$a ok $b bmc $g 1752185 $s 1156041
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 19 $c 6 $d 437-447 $e - $i 1996-3181 $m CNS & neurological disorders. Drug targets $n CNS Neurol Disord Drug Targets $x MED00173402
GRA    __
$a E-02/202.961/2017, E- 26/202.878/2018 $p Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro [FAPERJ]
GRA    __
$a 465.249/2014-0 $p National Institute of Science and Technology in Drugs and Medicines (INCTINOFAR)
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...